Vertex registers Phase 1 mass balance study of VX-407 in healthy volunteers

Vertex Pharmaceuticals had one new registry item posted this week.

• Vertex registered a Phase 1, open-label mass balance study of 14C-VX-407, a radiolabeled form of the drug, under the title "A Phase 1, Open-Label, Mass Balance Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 Following Single Oral Administration in Healthy Subjects"¹ (NCT07868926). The study lists Autosomal Dominant Polycystic Kidney Disease (ADPKD)¹ as its condition, but it will enroll 8 participants¹ who are healthy volunteers¹ rather than ADPKD patients. The trial is listed as not yet recruiting¹, with an estimated start date of 2026-10-19¹ and estimated primary completion on 2026-12-15¹.